Malaria vaccine in the offing
Scientists have announced that they are on the threshold of inventing a malaria vaccine. Researchers, however, are skeptical of Africa’s readiness to make use of it, where most of malaria-related deaths happen.
Nairobi: The World Health Organisation estimates there were 247 million cases of malaria in 2006, causing nearly one million deaths, mostly among African children.
- Malaria accounts for 20% of deaths of children under five in Africa; a new vaccine targeting this age group has entered the final stages of testing/ Photo credit: Julien Harneis/ Wikicommons
GlaxoSmithKline Biologicals' RTS,S is the first malaria vaccine to demonstrate a high level of efficacy. The vaccine is presently negotiating what will be the final hurdle before release as it enters Phase III trials in seven African countries.
RTS,S was specifically developed for use in Africa but Professor Wilfred Mbacham, a public health biotechnologist from the University of Yaoundé in Cameroon, says a failure by African governments to prepare adequately may rob millions of people access to the vaccine.
“As we pursue a breakthrough in the development of the vaccine, we need to begin speaking to African governments telling them how they should prepare to receive the vaccine. They need to prepare policy which will facilitate the inclusion of this vaccine into the Expanded Programme on Immunisation,” Mbacham says.
Regulatory systems in African countries which would be responsible for approving use of the vaccine are weak. Governments will also need to think how they will pay to inoculate populations, and master the details of where, how often, and in which groups of people malaria occurs in each country.
“African States will have to begin thinking about financing and how they will access the vaccine. While it is a possibility the Global Health Fund will provide money for this, governments need to explore other innovative financing methods,” Mbacham adds.
The RTS,S vaccine is intended primarily for infants; children under the age of five are the most vulnerable to malaria. After almost two decades of research and 10 years of trials, it is the first to reach Phase III, the final phase of testing.
“Phase II studies showed that RTS,S reduced clinical episodes of malaria by 53% over an eight-month follow-up period. And findings from the Phase II trial in southern Mozambique on children showed RTS,S was efficacious for at least 18 months in reducing clinical malaria by 35% and severe malaria by 49%.
“The vaccine has also shown a promising safety and tolerability profile when used alongside other WHO standard infant vaccines,” says Dr Joe Cohen a co-inventor of RTS,S.
The Phase III trial will evaluate the vaccine's efficacy in two groups of children, one cohort aged six to 12 weeks and the other aged five to 17 months.
Sixteen thousand children will take part in the trials; five thousand have already been recruited. The trials are being conducted in seven African countries, including Kenya, Burkina Faso, Tanzania, Mozambique, Ghana, Malawi and Gabon.
Health experts warn the news of the impending approval of the vaccine does not mean people can discard the current malaria prevention measures including use of insecticide treated mosquito nets (ITNs) and indoor residual spraying.
“These technologies have worked so far and communities need to continue using them. Should the vaccine be approved, these measures will continue to be used. Indeed, research is ongoing on strengthening the insecticides and making the ITNs longer lasting,” says Michael MacDonald from the malaria programme of the US Agency for International Development.
